Barz IVF Center for Embryo Research and Infertility Treatment, Koya Street, Brayate, Erbil 44001, Kurdistan, Iraq.
College of Medicine, University of Baghdad, Baghdad 10007, Iraq.
Endocrine. 2017 Dec;58(3):448-457. doi: 10.1007/s12020-017-1446-7. Epub 2017 Oct 13.
Anti-sperm antibodies (ASA) in men impair not only sperm motility but also fertilization and conception. However, utilization of corticosteroids to suppress ASA has shown variable pregnancy outcomes. This controversy is also extended to include the usefulness of conventional in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) in treatments of men with ASA. This study was therefore designed to define factors contributing to these inconsistent results.
Infertile men having ASA (n = 241) were randomly assigned for treatment with or without prednisolone for three cycles each of 21 days of their partner's menstrual cycles. Control and treated men underwent then human sperm penetration assay (SPA), of hamster oocytes, to diagnose men with impaired sperm fusogenic capacity. Men with positive or negative SPA results were admitted to conventional IVF or ICSI programs, respectively.
Treated patients had improved sperm motility and progressive motility when compared to control patients (P < 0.001). Fertilization (P = 0.04), embryo cleavage (P = 0.01), and chemical (P = 0.02) and clinical (P = 0.04) pregnancy rates were higher in treated patients than in control patients undergoing conventional IVF but not ICSI cycles.
Men with ASA may also have compromised sperm fusogenic capacity, which can mask the clinical significance of corticosteroids. Corticosteroid administration in men with ASA, but without compromised sperm fusogenic capacity, improves conventional IVF but not ICSI outcomes; the reason being that ICSI bypasses issues of compromised fusogenic capacity. Inclusion of SPA in infertility clinics that offer both conventional IVF and ICSI services may be useful to identify which patients with ASA benefit from corticosteroid treatments.
男性抗精子抗体 (ASA) 不仅会损害精子活力,还会影响受精和受孕。然而,使用皮质类固醇抑制 ASA 的效果显示出不同的妊娠结局。这种争议也扩展到包括传统体外受精 (IVF) 和卵胞浆内单精子注射 (ICSI) 在治疗 ASA 男性中的应用。因此,这项研究旨在确定导致这些不一致结果的因素。
将 241 名患有 ASA 的不育男性随机分配接受或不接受泼尼松龙治疗,每个周期为 21 天,共三个周期。对照组和治疗组男性随后接受人精子穿透试验 (SPA) 和仓鼠卵试验,以诊断精子融合能力受损的男性。SPA 结果阳性或阴性的男性分别被纳入常规 IVF 或 ICSI 计划。
与对照组相比,治疗组患者的精子运动能力和前向运动能力得到改善(P<0.001)。受精率(P=0.04)、胚胎分裂率(P=0.01)、化学妊娠率(P=0.02)和临床妊娠率(P=0.04)在接受治疗的患者中均高于接受常规 IVF 但未接受 ICSI 周期的患者。
ASA 男性可能还存在精子融合能力受损的情况,这可能掩盖了皮质类固醇的临床意义。在没有精子融合能力受损的 ASA 男性中使用皮质类固醇可改善常规 IVF 但不能改善 ICSI 结局;原因是 ICSI 绕过了融合能力受损的问题。在提供常规 IVF 和 ICSI 服务的不孕症诊所中纳入 SPA,可能有助于识别哪些 ASA 患者受益于皮质类固醇治疗。